Massive	massive	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
and	and	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
after	after	O	O	O	O
oral	oral	O	O	O	O
bisphosphonate	bisphosphonate	O	O	OTHERS	I
(	(	O	O	O	O
alendronate	alendronate	O	O	OTHERS	I
)	)	O	O	O	O
administration	administration	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
focal	focal	O	O	OTHERS	I
segmental	segmental	O	DISEASE	OTHERS	I
glomerulosclerosis	glomerulosclerosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
61-year-old	61-year-old	O	O	O	O
Japanese	japanese	O	O	O	O
man	man	O	O	O	O
with	with	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
focal	focal	O	O	OTHERS	I
segmental	segmental	O	DISEASE	OTHERS	I
glomerulosclerosis	glomerulosclerosis	O	DISEASE	OTHERS	I
was	was	O	O	O	O
initially	initially	O	O	O	O
responding	responding	O	O	O	O
well	well	O	O	O	O
to	to	O	O	O	O
steroid	steroid	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
amount	amount	O	O	O	O
of	of	O	O	O	O
daily	daily	O	O	O	O
urinary	urinary	O	O	O	O
protein	protein	O	O	O	O
decreased	decreased	O	O	O	O
from	from	O	O	O	O
15.6	15.6	O	O	O	O
to	to	O	O	O	O
2.8	2.8	O	O	O	O
g.	g.	O	O	O	O
Within	within	O	O	O	O
14	14	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
oral	oral	O	O	O	O
bisphosphonate	bisphosphonate	O	O	OTHERS	I
(	(	O	O	O	O
alendronate	alendronate	O	O	OTHERS	I
sodium	sodium	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
administration	administration	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
amount	amount	O	O	O	O
of	of	O	O	O	O
daily	daily	O	O	O	O
urinary	urinary	O	O	O	O
protein	protein	O	O	O	O
increased	increased	O	O	O	O
rapidly	rapidly	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
12.8	12.8	O	O	O	O
g	g	O	O	O	O
with	with	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

After	after	O	O	O	O
discontinuing	discontinuing	O	O	O	O
the	the	O	O	O	O
oral	oral	O	O	O	O
alendronate	alendronate	O	O	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
underwent	underwent	O	O	O	O
six	six	O	O	O	O
cycles	cycles	O	O	O	O
of	of	O	O	O	O
hemodialysis	hemodialysis	O	O	O	O
and	and	O	O	O	O
four	four	O	O	O	O
cycles	cycles	O	O	O	O
of	of	O	O	O	O
LDL	ldl	O	O	O	O
apheresis	apheresis	O	O	O	O
.	.	O	O	O	O

Urinary	urinary	O	O	O	O
volume	volume	O	O	O	O
and	and	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
recovered	recovered	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
normal	normal	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
urinary	urinary	O	O	O	O
protein	protein	O	O	O	O
disappearing	disappearing	O	O	O	O
completely	completely	O	O	O	O
within	within	O	O	O	O
40	40	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
report	report	O	O	O	O
demonstrates	demonstrates	O	O	O	O
that	that	O	O	O	O
not	not	O	O	O	O
only	only	O	O	O	O
intravenous	intravenous	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
also	also	O	O	O	O
oral	oral	O	O	O	O
bisphosphonates	bisphosphonates	O	O	OTHERS	I
can	can	O	O	O	O
aggravate	aggravate	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
and	and	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

